An Unusual Case of Allergic Reaction to Anakinra in a Patient with Tumor Necrosis Factor Receptor-1 Associated Periodic Syndrome (TRAPS) and Subsequent Canakinumab Treatment

  • Marta Mejias Trueba Pharmacy Service, Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen del Rocío, Seville, Spain
  • Marta Alonso Moreno Pharmacy Service, Hospital Universitario Virgen del Rocío, Seville, Spain
  • Noemi Garrido Puñal Rheumatology Service, Hospital Universitario Virgen del Rocío, Seville, Spain
  • Maria Soriano Martinez Pharmacy Service, Hospital Universitario Virgen del Rocío, Seville, Spain
DOI: https://doi.org/10.12890/2020_001668

Keywords

TRAPS syndrome, anakinra, allergic reaction, canakinumab

Abstract

Tumor necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) is a rare hereditary systemic autoinflammatory disease (SAID). Treatment is based on corticosteroids, but often requires the addition of a biologic drug (anti-TNF agent, IL-1 receptor antagonist, etc) to achieve symptom control. The addition of the second drug is not clearly defined and must take into account the characteristics and preferences of the patient. We describe a patient with TRAPS and an allergic reaction to anakinra which was difficult to manage clinically while alternative treatment was being identified.

VIEW THE ENTIRE ARTICLE

References

  • Gattorno M, Obici L, Cattalini M, Tormey V, Abrams K, Davis N, et al. Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study. Ann Rheum Dis 2017;76(1):173–178.
  • Cantarini L, Lucherini OM, Muscari I, Frediani B, Galeazzi M, Brizi, MG, et al. Tumour necrosis factor receptor-associated periodic syndrome (TRAPS): state of the art and future perspectives. Autoimmun Rev 2012;12(1):38–43.
  • Coutinho J, Chorão RS, Oliveira M, Santos CR. Treating TNF receptor associated periodic fever syndrome in end-stage renal failure. Case Rep Nephrol 2019;2019;6819476.
  • Ozen S, Kuemmerle-Deschner JB, Cimaz R, Livneh A, Quartier P, Kone-Paut I, et al. International retrospective chart review of treatment patterns in severe FMF, TRAPS and MKD/HIDS. Arthritis Care Res (Hoboken) 2017;69(4):578–586.
  • Orphanet. The portal for rare diseases and orphan drugs. Available from: https://www.orpha.net/consor4.01/www/cgi-bin/?lng=EN (accessed 4 May 2020).
  • Vila AT, Puig L, Fernández-Figueras MT, Laiz AM, Vidal D, Alomar A. Adverse cutaneous reactions to anakinra in patients with rheumatoid arthritis: clinicopathological study of five patients. Br J Dermatol 2005;153:417–423.
  • Wendling D, Jorgensen C. Treatment of rheumatoid arthritis by interleukin-1 receptor antagonist. Rev Med Interne 2002;23:1006–1011.
  • Agencia Española de Medicamentos y Productos Sanitarios - CIMA. Kineret 100 mg/0.67 ml solution for injection in pre-filled syringes. Available from: https://cima.aemps.es/cima/publico/detalle.html?nregistro=102203006 (accessed 4 May 2020).
  • Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004;350:2167–2179.
  • Benedetti FD, Gattorno M, Anton J, Ben-Chetrit E, Frenkel J, Hoffman HM, et al. Canakinumab for the treatment of autoinflammatory recurrent fever syndromes. N Engl J Med 2018;378:1908–1919.

    • Published: 2020-07-29

    Issue: Vol 7 No 10 (view)

    Section: Articles

    How to cite:
    1.
    Mejias Trueba M, Alonso Moreno M, Garrido Puñal N, Soriano Martinez M. An Unusual Case of Allergic Reaction to Anakinra in a Patient with Tumor Necrosis Factor Receptor-1 Associated Periodic Syndrome (TRAPS) and Subsequent Canakinumab Treatment. EJCRIM 2020;7 doi:10.12890/2020_001668.